Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis

NCT01856634 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Multidrug Resistant Tuberculosis
Pediatric

Interventions

DRUG: 100 mg Delamanid
DRUG: 50 mg Delamanid
DRUG: 25 mg Pediatric Formulation Delamanid
DRUG: 10 mg Delamanid Pediatric Formulation
DRUG: 5 mg Delamanid Pediatric Formulation
DRUG: Optimized Background Regimen

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.